The University of Chicago Header Logo

Connection

Marina Chiara Garassino to B7-H1 Antigen

Back to Details
This is a "connection" page, showing publications Marina Chiara Garassino has written about B7-H1 Antigen.
Marina Chiara Garassino
Connection Strength
3.620
B7-H1 Antigen
  1. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res. 2019 02 01; 25(3):989-999.
    View in: PubMed
    Score: 0.529
  2. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024 Aug; 19(8):1228-1241.
    View in: PubMed
    Score: 0.195
  3. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. ESMO Open. 2022 12; 7(6):100645.
    View in: PubMed
    Score: 0.177
  4. Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 11; 23(7):e489-e499.
    View in: PubMed
    Score: 0.173
  5. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncol. 2021 Apr; 17(10):1165-1184.
    View in: PubMed
    Score: 0.157
  6. At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer. Cancer Immunol Res. 2021 03; 9(3):261-264.
    View in: PubMed
    Score: 0.156
  7. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021 02 20; 39(6):619-630.
    View in: PubMed
    Score: 0.156
  8. Regulation of PD-L1 Expression by NF-?B in Cancer. Front Immunol. 2020; 11:584626.
    View in: PubMed
    Score: 0.154
  9. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clin Lung Cancer. 2021 03; 22(2):e180-e192.
    View in: PubMed
    Score: 0.153
  10. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020 11 15; 126(22):4867-4877.
    View in: PubMed
    Score: 0.152
  11. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. Clin Lung Cancer. 2020 09; 21(5):e456-e463.
    View in: PubMed
    Score: 0.147
  12. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. J Thorac Oncol. 2019 08; 14(8):1390-1399.
    View in: PubMed
    Score: 0.138
  13. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019 May; 75:39-51.
    View in: PubMed
    Score: 0.137
  14. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clin Cancer Res. 2019 04 01; 25(7):2166-2173.
    View in: PubMed
    Score: 0.135
  15. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018 04; 19(4):521-536.
    View in: PubMed
    Score: 0.128
  16. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 09; 373(2):123-35.
    View in: PubMed
    Score: 0.105
  17. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. J Immunother Cancer. 2025 Feb 04; 13(2).
    View in: PubMed
    Score: 0.052
  18. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
    View in: PubMed
    Score: 0.050
  19. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024 02 16; 30(4):824-835.
    View in: PubMed
    Score: 0.048
  20. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT). Lung Cancer. 2024 01; 187:107441.
    View in: PubMed
    Score: 0.048
  21. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. Eur J Cancer. 2023 12; 195:113404.
    View in: PubMed
    Score: 0.047
  22. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 09; 24(9):989-1001.
    View in: PubMed
    Score: 0.047
  23. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. J Immunother Cancer. 2023 06; 11(6).
    View in: PubMed
    Score: 0.046
  24. The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. Clin Lung Cancer. 2023 06; 24(4):381-387.
    View in: PubMed
    Score: 0.045
  25. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur J Cancer. 2022 12; 177:175-185.
    View in: PubMed
    Score: 0.044
  26. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. Front Immunol. 2022; 13:987639.
    View in: PubMed
    Score: 0.044
  27. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. J Thorac Oncol. 2021 08; 16(8):1369-1378.
    View in: PubMed
    Score: 0.040
  28. Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes? Ann Oncol. 2021 06; 32(6):814-816.
    View in: PubMed
    Score: 0.039
  29. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). Clin Lung Cancer. 2021 07; 22(4):301-312.e8.
    View in: PubMed
    Score: 0.039
  30. Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. Clin Cancer Res. 2021 01 15; 27(2):492-503.
    View in: PubMed
    Score: 0.038
  31. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab. Acta Oncol. 2020 Sep; 59(9):1058-1063.
    View in: PubMed
    Score: 0.037
  32. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019 10; 20(10):1395-1408.
    View in: PubMed
    Score: 0.035
  33. BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience. J Thorac Oncol. 2019 03; 14(3):e57-e59.
    View in: PubMed
    Score: 0.034
  34. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. Target Oncol. 2018 12; 13(6):795-800.
    View in: PubMed
    Score: 0.034
  35. Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. Eur Respir J. 2018 02; 51(2).
    View in: PubMed
    Score: 0.032
  36. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017 Aug 20; 35(24):2781-2789.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.